UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Teclistamab – myélome multiple en rechute ou réfractaire après au moins trois traitements antérieurs

Bulletin du cancer, 2023-09, Vol.110 (9), p.871-872

2023

Volltextzugriff (PDF)

MM-344 Real-World Patient Profile and Step-Up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma (MM) in a Hospital Setting in the US: Premier Healthcare Database Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S491-S491

2023

Volltextzugriff (PDF)

MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S480-S481

2023

Volltextzugriff (PDF)

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia

Frontiers in immunology, 2021-05, Vol.12, p.605766-605766

2021

Volltextzugriff (PDF)

Therapeutic roles of antibody drug conjugates (ADCs) in relapsed/refractory lymphomas

Hematology/oncology and stem cell therapy, 2023-01

2023

Volltextzugriff (PDF)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction

Frontiers in immunology, 2021-02, Vol.12, p.627764

2021

Volltextzugriff (PDF)

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

Leukemia & lymphoma, 2021-09, Vol.62 (11), p.2727-2736

2021

Volltextzugriff (PDF)

AML-212: Combination of Venetoclax and Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: Single-Center Clinical Experience

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S192-S193

2020

Volltextzugriff (PDF)

Approaching the first relapse after autologous transplant in multiple myeloma

Advances in cell and gene therapy, 2021-01, Vol.4 (1), p.n/a

2021

Volltextzugriff (PDF)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy

European journal of haematology, 2023-10, Vol.111 (4), p.573-582

2023

Volltextzugriff (PDF)

The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

British journal of haematology, 2017-03, Vol.176 (5), p.750-758

2017

Volltextzugriff (PDF)

Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis

British journal of haematology, 2022-09, Vol.198 (5), p.838-846

2022

Volltextzugriff (PDF)

Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?

British journal of haematology, 2023-01, Vol.200 (1), p.13-14

2023

Volltextzugriff (PDF)

Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia

Transfusion medicine and hemotherapy, 2024-02, Vol.51 (1), p.55-60

2024

Volltextzugriff (PDF)

Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma

Journal of blood medicine, 2024-01, Vol.15, p.407-419

2024

Volltextzugriff (PDF)

New hopes in relapsed refractory primary central nervous system lymphoma

Current opinion in oncology, 2023-09, Vol.35 (5), p.364-372

2023

Volltextzugriff (PDF)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma

International journal of hematology- oncology and stem cell research, 2023-07, Vol.17 (3), p.194-199

2023

Volltextzugriff (PDF)

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations

Frontiers in immunology, 2023-08, Vol.14, p.1237738

2023

Volltextzugriff (PDF)

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia

Clinical lymphoma, myeloma and leukemia, 2019-09, Vol.19 (9), p.560-569

2019

Volltextzugriff (PDF)

Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy

Annals of hematology, 2015-05, Vol.94 (5), p.803-812

2015

Volltextzugriff (PDF)

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia

Leukemia research, 2024-06, Vol.141, p.107505, Article 107505

2024

Volltextzugriff (PDF)

Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy

Leukemia & lymphoma, 2021-03, Vol.62 (4), p.828-836

2021

Volltextzugriff (PDF)

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting

Journal of comparative effectiveness research, 2024-02, Vol.13 (2), p.e230142-e230142

2024

Volltextzugriff (PDF)

Relapse/Refractory Paediatric B-ALL Case with CD19− Phenotype Switching Indicating the Importance of Appropriate Diagnostic Approach and Targeted Treatment Adjustment—Case Report

International journal of molecular sciences, 2023-09, Vol.24 (17), p.13322

2023

Volltextzugriff (PDF)

Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (study T2008‐002 NECTAR)

Pediatric blood & cancer, 2022-11, Vol.69 (11), p.e29901-n/a

2022

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(72)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Humans
(41)
Hematology
(30)
Relapse/refractory
(27)
Oncology
(21)
Female
(18)
Male
(18)
Aged
(17)
Chemotherapy
(15)
Middle Aged
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Recurrence
(14)
Adult
(12)
Patients
(12)
Multiple Myeloma
(11)
Prognosis
(11)
Relapse
(11)
Remission
(10)
Stem Cell Transplantation
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Teclistamab – myélome multiple en rechute ou réfractaire après au moins trois traitements antérieurs

MM-344 Real-World Patient Profile and Step-Up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma (MM) in a Hospital Setting in the US: Premier Healthcare Database Study

MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia

Therapeutic roles of antibody drug conjugates (ADCs) in relapsed/refractory lymphomas

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

AML-212: Combination of Venetoclax and Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: Single-Center Clinical Experience

Approaching the first relapse after autologous transplant in multiple myeloma

Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy

The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis

Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?

Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia

Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma

New hopes in relapsed refractory primary central nervous system lymphoma

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia

Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia

Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting

Relapse/Refractory Paediatric B-ALL Case with CD19− Phenotype Switching Indicating the Importance of Appropriate Diagnostic Approach and Targeted Treatment Adjustment—Case Report

Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (study T2008‐002 NECTAR)

Suchergebnisse filtern